Alagille Syndrome

FDA label expansion makes maralixibat available for infants 3 months and older with ALGS

The U.S. Food and Drug Administration approved a reduction in age from 1 year to 3 months for maralixibat (Livmarli; Mirum) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), according to a press release. The label expansion was based on data from the RISE...